HHS
Harte Hanks, Inc.
There isn't enough reported data to score HHS yet.
META
Meta Platforms, Inc.
META's fundamentals are mixed, but it looks cheap: trading at 21x earnings, below its usual 27x. Analysts expect earnings growth, though they disagree widely on how much.
HHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HHS's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HHS PE Valuation
HHS has no meaningful PE right now: it lost money over the past year.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
HHS Forward outlook
There aren't enough analyst estimates for HHS to show an outlook.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
HHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.76 | -$0.37 |
| Q1 2026 | -$0.14 | +$4.04 |
| Q4 2025 | -$0.11 | +$4.04 |
| Q3 2025 | -$0.72 | +$3.38 |
| Q2 2025 | -$0.39 | +$3.65 |
| Q1 2025 | -$4.18 | -$4.06 |
| Q4 2024 | -$4.15 | -$3.94 |
| Q3 2024 | -$4.10 | -234% |
HHS is still losing money, but far less than before: $0.76 per share over the past year, against $4.27 at its worst in late 2019.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META has the edge over HHS on earnings quality, reporting a profit while its opponent remains loss making.
HHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $38M | -1.7% |
| Q1 2026 | $37.3M | -10% |
| Q4 2025 | $39.9M | -15% |
| Q3 2025 | $39.5M | -17% |
| Q2 2025 | $38.6M | -14% |
| Q1 2025 | $41.6M | -8.6% |
| Q4 2024 | $47.1M | -4.8% |
| Q3 2024 | $47.6M | +1.1% |
HHS's revenue has slid since its 2022 peak: $38M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -12% | -12 points |
| Q1 2026 | -2.1% | -2 points |
| Q4 2025 | -0.3% | +3 points |
| Q3 2025 | 1.3% | -2.7 points |
| Q2 2025 | 0.1% | -3 points |
| Q1 2025 | -0.1% | -0.9 points |
| Q4 2024 | -3.3% | +1.3 points |
| Q3 2024 | 4% | -2.2 points |
HHS's operating margin was −12% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over HHS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over HHS on profitability, with a higher operating margin.
HHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$3M |
| Q1 2026 | -$922K | +$1K |
| Q4 2025 | -$686K | -120% |
| Q3 2025 | $2.2M | +$7M |
| Q2 2025 | -$5.1M | -648% |
| Q1 2025 | -$923K | +$5.3M |
| Q4 2024 | $3.4M | +13% |
| Q3 2024 | -$4.9M | -474% |
HHS has burned cash in six of the last eight quarters: −$1M over the past year, against −$7M the year before.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META has the edge over HHS on cash generation, producing positive trailing cash flow while its opponent burns cash.
HHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +15K shares |
| 1 year | +0.7% | +49K shares |
| 3 years | -1% | -74K shares |
| 5 years | +3.3% | +238K shares |
| Available history | +18% | +1.1M shares |
HHS has 7M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $491,000 |
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has the edge over HHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
HHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
HHS has more cash than debt.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
HHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 72.7 | Neutral |
HHS's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
HHS PE vs Communication Services Sector
| Metric | HHS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 16x | — |
HHS has no meaningful PE right now: it lost money over the past year.
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
HHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.21 | 4.3% below |
| 20 week MA | $3.66 | 10% above |
| 50 week MA | $3.14 | 28% above |
| 100 week MA | $3.70 | 8.9% above |
| 200 week MA | $5.54 | 27% below |
HHS has the edge over META on trend strength, trading above more of its moving averages.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has fallen below most of its moving averages, though it's still 21% above its 200-week average.
HHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.46 | $2.55 | -26% |
| 2021 | $2.55 | $8.17 | +220% |
| 2022 | $8.17 | $11.5 | +41% |
| 2023 | $11.5 | $6.79 | -41% |
| 2024 | $6.79 | $5.38 | -21% |
| 2025 | $5.38 | $3.32 | -38% |
| 2026 YTD | $3.32 | $4.03 | +21% |
HHS has the edge over META on returns for 2026, with the stronger performance.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META's yearly returns have swung widely, from +200% in 2023 to −65% in 2022. It's down 6% so far in 2026.